Calyxt, Inc. (CLXT): Price and Financial Metrics
CLXT Price/Volume Stats
Current price | $6.30 | 52-week high | $7.77 |
Prev. close | $5.97 | 52-week low | $1.25 |
Day low | $6.01 | Volume | 254,600 |
Day high | $7.77 | Avg. volume | 139,308 |
50-day MA | $3.59 | Dividend yield | N/A |
200-day MA | $2.64 | Market Cap | 31.34M |
CLXT Stock Price Chart Interactive Chart >
Calyxt, Inc. (CLXT) Company Bio
Calyxt, Inc., an agriculture biotechnology company, develops healthier specialty food ingredients and agricultural food crops using gene editing technology for plants. It engages in the development of high oleic soybeans, powdery mildew resistant wheat, cold storable potatoes, high fiber wheat, reduced browning potatoes, and herbicide tolerant wheat. The Company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. The company was founded in 2010 and is based in New Brighton, Minnesota
Latest CLXT News From Around the Web
Below are the latest news stories about CALYXT INC that investors may wish to consider to help them evaluate CLXT as an investment opportunity.
Calyxt Announces Stockholder Approval of Merger With CibusCalyxt, Inc. (Nasdaq: CLXT) ("Calyxt" or the "Company") today announced the results of the special meeting of its stockholders held on May 18, 2023. At the special meeting, Calyxt's stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Class A common stock and Class B common stock to the equity holders of Cibus Global, LLC ("Cibus") as part of the previously announced proposed merger with Cibus. |
Calyxt Reports First Quarter 2023 Financial Results and Provides Corporate UpdateCalyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced operating and financial results for its first quarter ended March 31, 2023. |
Calyxt Completes One-for-Ten Reverse Stock SplitCalyxt, Inc. (Nasdaq: CLXT) ("Calyxt" or the "Company") today announced that it has completed the previously announced reverse stock split of Calyxt's common stock, par value $0.0001 per share ("Common Stock"), at a ratio of 1-for-10. The reverse stock split was previously approved by the Company's stockholders at the annual meeting of shareholders on June 1, 2022. |
Calyxt, Inc. Announces Effectiveness of Registration Statement on Form S-4 in Connection with Merger with Cibus Global LLCCalyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that the registration statement on Form S-4, initially filed with the U.S. Securities and Exchange Commission ("SEC") by Calyxt on February 14, 2023, and amended on April 14, 2023 (as amended, the "Registration Statement"), has been declared effective by the SEC. |
Calyxt Announces Effective Date of Reverse Stock SplitCalyxt, Inc. (Nasdaq: CLXT) ("Calyxt" or the "Company") today announced that it will proceed with the 1-for-10 reverse stock split previously approved by the Company's shareholders at the annual meeting of shareholders on June 1, 2022. Calyxt plans to file an amendment to its certificate of incorporation to effectuate the reverse stock split after the close of trading on April 24, 2023, and Calyxt's common stock, par value $0.0001 per share, will begin trading on an adjusted basis giving effect |
CLXT Price Returns
1-mo | N/A |
3-mo | N/A |
6-mo | N/A |
1-year | 75.00% |
3-year | -89.34% |
5-year | -96.42% |
YTD | N/A |
2023 | 0.00% |
2022 | -93.08% |
2021 | -49.53% |
2020 | -39.80% |
2019 | -32.34% |
Continue Researching CLXT
Want to do more research on Calyxt Inc's stock and its price? Try the links below:Calyxt Inc (CLXT) Stock Price | Nasdaq
Calyxt Inc (CLXT) Stock Quote, History and News - Yahoo Finance
Calyxt Inc (CLXT) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...